In contrast, inhibition of MET activity with capmatinib (highly sensitive MET inhibitor, FDA approved for NSCLC treatment) restored sensitivity of NCI-H1703R, SNU-16R, and RT-112R cells to CPL304110 (Figures 3B, S3B). The gene discussed is MET; the disease is non-small cell lung carcinoma.